



Investor Presentation

December 2018

LOOKING AT
MENTAL HEALTH,
OBJECTIVELY

Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Medibio Limited (**ASX:MEB**) (**OTCQB: MDBIF**). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Foreign Offer Restrictions

This Presentation does not constitute an offer of New Securities (**New Securities**) of the Company in any jurisdiction in which it would be unlawful. In particular, this Presentation may not be distributed to any person, and the New Securities may not be offered or sold, in any country outside Australia except to the extent permitted below.

Hong Kong

WARNING: This Presentation has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Future Ordinance (Cap. 571) of the Laws of Hong Kong (the **SFO**). No action has been taken in Hong Kong to authorise or register this Presentation or to permit the distribution of this Presentation or any documents issued in connection with it. Accordingly, the New Securities have not been and will not be offered or sold in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance). No advertisement, invitation or document relating to the New Securities has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Securities that are or are intended to be disposed of only to person outside Hong Kong or only to professional investors. No person allotted New Securities may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities. The contents of this Presentation have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this Presentation, you should obtain independent professional advice.

United States

This Presentation may not be distributed or released in the United States. This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to any person who is acting for the account or benefit of any person in the United State (to the extent such person is acting for the account or benefit of a person in the United States), or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal. The New Securities have not been, or will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Securities may not be offered, sold or resold, directly or indirectly, in the United States or to persons acting for the account or benefit of a person in the United States (to the extent such persons hold ordinary shares in the Company and are acting for the account or benefit of a person in the United States), except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any applicable securities laws of any state or jurisdiction of the United States.



The mental health technology company leveraging objective digital biomarkers for products and services that assist in screening, diagnosing, monitoring, and managing of depression and other mental health conditions.

Medibio Update



New
Focus



Clear
Direction



New Path
Forward



**Path to
Commercialisation
CY 2019**



New Focus



- ▶ Eliminating Distractions as Quickly as Possible
- ▶ Challenge All Spending to Conserve Cash
- ▶ Prioritize Business Segments
- ▶ Strengthen Regulatory Path
- ▶ Open & Honest Communication to All


New Path Forward



- ▶ Right-Size the Business
- ▶ Ruthlessly Challenge All Spending
- ▶ Strengthen Regulatory Path
- ▶ Commercialisation in 2019



Quarterly Cash Burn - Fiscal Years 2018 & 2019



Corporate Structure

CAPITAL STRUCTURE (ASX:MEB) (OTCQB:MDBIF)

Market Cap	AU\$7.7M
Share price <i>as of 26 November 2018</i>	AU\$0.038
Shares on Issue	203M
Cash ¹	AU\$3.5M

1. Cash balance as of 31 October 2018.
2. Percentages based on available information, including share registry, options listing, ASX filings, and other reported data
3. Includes shares on issue and vested board & management options


Significant Institutional Investors

 Fidelity	9.1%
 Regal Funds Management	7.0%




Shareholder Mix^{2, 3}

Private Holders	57.2%
Institutional Holders	40.1%
Board and Management	2.7%

Scientific & Clinical Development Process



Regulatory Validation & Publications



Mayo Clinic Convergence Neuroscience 2018 Course



510K path
De Novo path

U.S. Regulatory Path to Commercialisation


FDA 510k Clearance Class I or II Device



- ▶ Use a “Predicate” Technology
- ▶ Technology Must Be Low-risk
- ▶ Typically 90 Days to Clearance
- ▶ Vast Majority of Medical Devices/ Technology

U.S. Regulatory Path to Commercialisation

FDA De Novo Clearance Class I or II Device



Commercial Opportunities

Australia

Illumen in Corporate Health Market



Small Start with Pilots

Need to Refine the Business Model

Provide Better Feedback

Develop IP in This Space

Refine Pricing Model for Revenue


Improve Partnership and Integration Opportunities

Manage Our Costs



Looking to Expand...

- Focus on Better Use of Biometrics
- Continue to Improve Biometric Algorithm (based on wearable data collected)



Commercial Opportunities

USA

with Regulatory Clearance



Two Paths:



De Novo

No Specific Timeline



510K Clearance

- **1 or more applications**
- **Expect clearance by 2019**
- **Lead to commercialisation in 2019**



Focus Will Be on Medical - Integrated Health Solutions



Will evaluate Corporate Health



Consumer in the Future

Board of Directors



CHRIS INDERMAUR
Chairman
B. Eng. (Mech.), Grad Dip Eng. (Chem.), LLB,
LLM, Grad Dip LP



PETER CARLISLE
Vice Chairman
Managing Director, Olympics &
Action Sports, Octagon Worldwide



DR FRANKLYN G PRENDERGAST
PhD MD, Non Executive Board Member
Former member board of Trustee and Board of Governors
Mayo Clinic and board member Eli Lilly



PATRICK KENNEDY
Non Executive Director
Former US Congressman
Founder, Kennedy Forum



MICHAEL PHELPS
Non Executive Director
Mental Health Advocate



ANDREW MAXWELL
Non Executive Director
MBA, MAcc, ACPA



DAVID KAYSEN
CEO & Managing Director



MELANIE LEYDIN
Company Secretary
B. Bus. (UTS), Grad. Dip. DP (UTS), CA, AGIA

Executive Team



DAVID KAYSEN
Chief Executive Officer



BRIAN MOWER
CFO
B.S., MAcc, CPA



ARCHIE DEFILLO
Chief Medical Officer



JEREMY SCHROETTER
Chief Technology Officer



LINDSEY HAGAN
Vice President Integrated Health



JENNIFER SOLITARIO
Senior Vice President Corporate Health



PATRICK MIDDEN
Chief Privacy Officer

SCIENTIFIC ADVISORY BOARD

External Advisors:

Martin Chapman, MBBS FRANZCP

Psychiatrist and Fellow of the **Royal Australian and New Zealand College of Psychiatrists**. As a medical administrator he has worked in both hospital and community settings in private and government sectors. His clinical practice is in the area of treatment resistant mood and anxiety disorders. He has taught in undergraduate and postgraduate Psychiatry with a focus in assisting primary care physicians in their management of mental health conditions. He has an interest in mental health system development and the role of new technologies in streamlining and providing clinical decision support.

Joel R. Ehrenkranz, M.D.

Endocrinologist on the faculty of the **University of Colorado School of Medicine** and a biotech entrepreneur in Salt Lake City, Utah. Dr. Ehrenkranz received his M.D. degree from Stanford and trained in internal medicine at Columbia University, neurology at Memorial Sloan Kettering Cancer Center, and endocrinology at the National Institutes of Health.

Mark A. Frye, M.D.

Chair of the Department of Psychiatry and Psychology at **Mayo Clinic**. He also serves as director of the Mayo Clinic Depression Center. Dr. Frye received his M.D. from the University of Minnesota and completed his psychiatric training at the Semel Institute for Neuroscience and Human Behavior at the David Geffen School of Medicine at UCLA. He subsequently completed a fellowship at the National Institute of Mental Health in Bethesda, Maryland with a research focus on the neurobiology of treatment resistant depression and bipolar disorder.

Lawrence Hunter, Ph.D.

Professor at the **University of Colorado** and directs the Computational Bioscience Program. He earned his degrees from Yale University, including B.A. in Psychology (cum laude); M.S. and M. Phil. and Ph.D. in Computer Science.

Wallace Mendelson, M.D.

Psychiatrist and author, and was formerly **Professor of Psychiatry and Clinical Pharmacology**, and director of the **Sleep Research Laboratory**, at the **University of Chicago**. Dr. Mendelson earned an MD degree from Washington University School of Medicine in St. Louis and completed a residency in psychiatry there as well. He has held professorships at Ohio State University and the State University of New York at Stony Brook, was Chief of the Section on Sleep Studies at the National Institute of Mental Health in Bethesda, MD, and Director of the Sleep Disorders Center at the Cleveland Clinic.

Marie Casey Olseth, M.D.

Currently in private practice as a Board Certified Adult Psychiatrist in the group practice that she owns. She earned her of Medicine degree from the University of Minnesota Medical School and completed her residency in General Psychiatry at the University of Minnesota and University of Wisconsin, Madison.

Giampaolo Perna, M.D., Ph.D.

Currently Chair of the Department of Clinical Neurosciences at **San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake)** and Academic Coordinator of Mental Health and Adjunct Professor at **Humanitas University (Milan)**, in Italy. He earned his degree in Medicine and Surgery at the State University of Milan, followed by Ph.D. and completed a residency in Psychiatry there as well. He is the Chair of WPA section on personalized psychiatry and Co-editor in chief of the Elsevier Journal “Personalized Medicine in Psychiatry”.

Internal Advisors:

Archie Defillo, M.D.

Currently the Chief Medical Officer at **Medibio Limited**. He has over 25 years of clinical experience with neurological diseases. For the past 13 years his efforts have been focused in neurological research. His research interests include cerebrovascular, stroke, neuro-trauma, brain oxygenation, metabolism and autonomic dysfunction. Based on his extensive academic work, in 2012, he was selected a scientific member of the Congress of Neurological Surgeons.

Franklyn Prendergast, M.D., Ph.D.

Currently a director on the **Medibio Limited** board and chair of the Scientific Advisory Board. Previously, he was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.

Dr. Prendergast earned his medical degree with honors from the University of West Indies. He attended Oxford University as a Rhodes Scholar, where he earned his masters degree in Physiology. After completing residency in Internal medicine at The Mayo Clinic in Rochester, Minnesota he earned a doctorate degree Biochemistry from the University of Minnesota/Mayo Graduate School.

Positions held: Chair, Department of Biochemistry and Molecular Biology; Director for Research Mayo Clinic (Rochester) (1989-1992). Board of Governors Mayo Clinic in Rochester; Mayo Clinic Board of Trustees (1992-2009); Mayo Clinic Board of Governors (1999-2006). Mayo Distinguished Investigator; Emeritus Director, Mayo Clinic Comprehensive Cancer Center and Mayo Center for Individualized Medicine.

In addition to his current role as a director on the Medibio board and chair of the Scientific Advisory Board, Dr. Prendergast holds numerous appointments with Industry and Extramural academic affiliations. He has extensive interactions over many years with National Institutes of Health (NIH); Board of Advisors for the Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of the National Cancer Institute; and the National Cancer Advisory Board.

Summary

THE CHALLENGE

21 million suicide attempts from mental illness
Of those, nearly 1 million are successful

THE SOLUTION

Biometric-based technology to identify, monitor and treat mental health conditions

THE SCIENCE

20+ years of scientific rigor

THE COMPANY


Ready to change the way the world looks at Mental Health,
OBJECTIVELY.

THE OPPORTUNITY

Corporate Health
64 million employees
Consumer Health
266 million lives
Integrated Health
450 million lives

THANK YOU

David B. Kaysen
CEO and Managing Director
dave.kaysen@Medibio.com.au
8696 Eagle Creek Circle
Savage . MN 55378 USA



Capital Raising

Capital Raising

Medibio is pleased to announce the Company has undertaken a two-tranche placement of converting notes (Converting Notes) to raise approximately \$2.5 million:

- Face Value of \$0.02 per Converting Note;
- Tranche 1 to raise approximately \$0.61m through the issue of ~30.39m Converting Notes under the Company's remaining LR7.1 capacity; and
- Tranche 2 to raise ~\$1.89m through the issue of 94.61m Converting Notes subject to receiving shareholder approval at the Company's Extraordinary General Meeting, anticipated to be on, or around, Tuesday 15 January 2019
- Further details regarding the terms of the Converting Notes are provided in the capital raising announcement released to ASX dated Monday, 10 December 2018

In addition, the Company has announced a 1-for-1 pro-rata non-renounceable entitlement offer (Entitlement Offer) to raise ~\$4.05m at \$0.02 per share to eligible shareholders as at the Record Date

- Net funds raised from the placement of the Converting Note and Entitlement Offer will be applied to:
 - Sales & marketing infrastructure;
 - New product development;
 - Expansion of the technology platform and infrastructure;
 - Regulatory clearances; and
 - Working capital
- Further details regarding the capital raising structure and timetable are provided on page 21 and 22

Capital Raising Details

Sources ^{1,2}	A\$m
Placement of Converting Notes	2.50
Entitlement Offer	4.05
Total Sources	6.55

Uses	A\$m
Sales & Marketing infrastructure for product commercialisation	2.30
Development of target new products	0.90
Expansion of technology platform and infrastructure	1.10
Regulatory clearances	1.10
Working capital	0.80
Broker costs	0.35
Total Uses	6.55

Offer Details	
Offer size and structure	<ul style="list-style-type: none"> A\$2.5m Placement of Converting Notes A\$4.05m 1-for-1 pro-rata non-renounceable entitlement offer (“Entitlement Offer”)
Offer price	<ul style="list-style-type: none"> Fixed price of A\$0.0200 per New Share for the Entitlement Offer 50.0% discount to last close (A\$0.0400) 50.7% discount to 5 day VWAP (A\$0.0406) 49.8% discount to 1 month VWAP (A\$0.0398) 68.3% discount to 3 month VWAP (A\$0.0631)
Entitlement Offer	<ul style="list-style-type: none"> The Entitlement Offer opens Tuesday, 18 December 2018 and closes on Thursday, 7 February 2019. Offer to eligible shareholders with a registered address in Australia, New Zealand and Hong Kong only “Top-Up Facility” available to shareholders Entitlements belonging to ineligible shareholders or those shareholders who elect not to take up their entitlement, will be offered for sale to Top-Up bids followed by a shortfall bookbuild on, or around, Friday, 8 February 2019
Record date	<ul style="list-style-type: none"> 7pm (AEDST³), Thursday, 13 December 2018
Underwriting	<ul style="list-style-type: none"> The Entitlement Offer is not underwritten
Ranking of new shares	<ul style="list-style-type: none"> New Shares issued will rank equally with existing Medibio shares in all respects
Top-Up Offer	<ul style="list-style-type: none"> Under the Entitlement Offer all eligible shareholders are entitled to subscribe for up to their 1-for-1 entitlement In addition, eligible shareholders may apply for Additional New Shares in excess of their entitlement through the Top Up offer, with such over-subscription to be satisfied out of any shortfall shares, subject to Board discretion and potential scale back
Director participation	<ul style="list-style-type: none"> Medibio’s Australian directors who are eligible to take-up their entitlements intend to take-up their entitlements

Notes:

- Assumes shareholder approval received for Tranche 2 placement of Converting Notes; and
- Assumes 100% take-up of the Entitlement Offer in conjunction with any Top-Up bids and bids under the Shortfall Bookbuild; and
- Australian Eastern Daylight Savings Time (AEDST).

Entitlement Offer

Event	Date
Announcement of placement of Converting Notes and Entitlement Offer	Monday, 10 December 2018
Entitlement Offer Ex-Date	Wednesday, 12 December 2018
Entitlement Offer Record Date ¹	7pm (AEDST), Thursday, 13 December 2018
Settlement of Converting Note – Tranche 1	Friday, 14 December 2018
Entitlement Offer opens	Tuesday, 18 December 2018
EGM to approve Converting Note – Tranche 2	On, or about, Tuesday 15 January 2019
Settlement of Converting Note – Tranche 2 ²	Tuesday, 22 January 2019
Entitlement Offer closes	5pm (AEDST), Thursday, 7 February 2019
Settlement of New Shares issued under the Entitlement Offer	Thursday, 14 February 2019
Commencement of trading of New Shares issued under the Entitlement Offer	Friday 15 February 2019

Notes:

- 1. Australian Eastern Daylight Savings Time (AEDST); and
- 2. Assumes shareholder approval received for Tranche 2 placement of Converting Notes





Appendix

The Challenge

IN ORGANISATIONS

Mental Health in the Workplace



The Challenge

IN SOCIETY

Stigma and lack of access are prevalent globally

21 million suicide attempts from mental illness

Of those, nearly 1 million are successful

In 2015, suicide was the



leading cause of death among 15 to 29 year-olds globally

300 MILLION
suffer from depression

1 in 13
suffer from anxiety

7.7 MILLION
PTSD sufferers in the United States alone

The Challenge

IN THE HEALTHCARE SYSTEM

Only **1 psychiatrist per 100,000 people** in over half the countries in the world

40% of countries have less than one hospital bed reserved for mental disorders
per 10,000 people

Out of **350 million** patients globally **< 7%** receive optimal treatment



50%
are never diagnosed



30%
are incorrectly diagnosed



\$94.5
BILLION

direct cost to treat Major Depressive Disorder (MDD) annually in the USA



\$12.6
BILLION

direct cost to treat depression annually in Australia

The Science

PIONEERING RESEARCH

Mental Illness and Biomarkers
in the Human Body

Physiology

Our approach exploits features of cardiovascular physiology influenced directly by the autonomic nervous system and susceptible to disruption during sleep, as a source of biometrics that correlate with onset and existence of mental dysfunction.

20+ years of data collected







Data Science

Our approach focuses on using Artificial Intelligence to monitor mental illness types (such as depression, PTSD, anxiety and stress) and potential physiological metrics, so we can predict irregularity and future recurrent episodes.

A comprehensive patent suite
CHR, technology, and diagnostics

The relationship between psychiatric illness and the circadian pattern of heart rate.
Hans G . Stampfer, Australian and New Zealand Journal of Psychiatry 1998; 32:187-198.

Clinical Background

PAST/ PRESENT STUDIES	PARTNERS	ACCURACY	STUDY PURPOSE
<p>Prospective Clinical Validation Trial</p> <p>DX04 DEPRESSION - Prospective Study</p> <p>May 2018</p> <p>220 patients</p>	<p>8 clinical study partners</p>	<p>70% (56-84%)</p>	<p>Prospective, blinded, case controlled, cross sectional clinical validation study to support the FDA De Novo submission as an aide in the diagnosis of depression in a normal environment</p>
<p>Retrospective Data Analysis</p> <p>Retrospective PSG+HRV in sleep lab for DEPRESSION</p> <p>November 2016</p> <p>889 patients</p>	<p></p>	<p>86%</p>	<p>Retrospective, un-blinded analysis to identify depressed from non-depressed subjects in a controlled sleep lab environment using PSG + HRV</p>
<p>Proof of Concept</p> <p>MACH-3 Depression - Prospective study</p> <p>August 2017</p> <p>60 patients</p>	<p></p>	<p>82%</p>	<p>Prospective, proof of concept study using HRV to diagnose depression In a primary care setting</p>
<p>MACH-2 DEPRESSION - retrospective study</p> <p>December 2016</p> <p>26 patients</p>	<p></p>	<p>81%</p>	<p>Retrospective hypothesis study to identify depressed patients</p>
<p>Foundational Learning</p> <p>SLEEP STAGING Observational Study using ECG Data</p> <p>June 2016</p> <p>7,500 subject sleep records</p>	<p></p>	<p>86-95%</p>	<p>Retrospective data analysis to identify sleep staging using ECG data</p>
<p>Versus 33-50% – Diagnostic accuracy in the Primary Care Setting¹</p> <p>(1) Depression in Primary Care Vol 1: U.S. Department of Health</p>			

Clinical Validation DX04 FDA Study



Clinical Validation



1. Based on employment in USA and Australia
2. Based on adult population in USA and Australia
3. World Health Organization's global population of mental disorders

Corporate Health App



An objective digital biometric analysis and mental wellness assessment provided to the employee, paid for by their employer.

- Mental wellness survey and assessment
- Biometric monitoring with history tracking
- Optional telepsych debriefing of results
- Communications toolbox for rollout
- Organisational dashboard analytics
- Recommendations for employer

THREE-STEP PROCESS



ASSESS



CONNECT



DISCOVER





1. Based on employment in USA and Australia
2. Based on adult population in USA and Australia
3. Based on people in the world currently suffering from a mental health condition

Corporate Health App



REAL-TIME ORGANISATIONAL DASHBOARD

- Detailed analytics to Corporate Customers at Organisational level
- De-identified aggregate data to enable informed decision making
- Ability to filter and view demographical subsections (eg. Females, aged 18-35)
- Improve team performance and employee well-being



Corporate Health App



WHY IT'S NEEDED

In any workforce there are various levels of stress that can affect individual/team mental wellness.

Employers are

- Increasing pressure to meet internal/external targets and promoting high performing culture
- Requiring higher levels of mental fitness & time requirements at work and at home
- Expecting frequent travel and project deployment

...While managing

- Wide geographical distribution
- Turnover
- Well-being programs that aren't data-driven or specific to your organisation


HOW IT WORKS

Employees:

- Employees track biometrics over time with a wearable device
- Access to mental wellness assessments via mobile or web
- Learn about strategies to better cope with managing life at work, personal development plans, stress, and strain
- Empowered to measure, monitor, and improve wellness

Organizations:

- Dynamic understanding - know what your workforce needs AND how to help
- Optimize workforce performance, minimize risk, and offer better care for employees



WHAT IT DOES

Employees:

- Track and monitor wellness
- Improve through tailored resources
- Identify positive influences of personal lifestyle modifications

Organizations:

- Access a de-identified dashboard of employee well-being
- Make informed decisions based on workforce data
- Monitor impact of decisions made, programs implemented
- Provide metrics on workforce capability to clients, suppliers, insurers etc.



THANK YOU

8696 Eagle Creek Circle
Savage, MN 55378 USA

medibio.com.au

LOOKING AT
MENTAL HEALTH,
OBJECTIVELY